
Alentis Appoints Alberto Toso Chief Scientific Officer
BASEL, Switzerland – Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective immediately. Alberto joined Alentis in 2021 as Head of Oncology. “It is becoming increasingly clear that #Claudin-1 has tremendous potential for treating cancer. As CSO, it is my objective to harness the … Continue reading Alentis Appoints Alberto Toso Chief Scientific Officer